AIMM AutoImmune Inc. featured news, full reports, and detailed charts
AutoImmune Inc. (AIMM/AIMM.OB) Wrap Up:
AutoImmune Inc., a development stage company, develops products for the treatment of autoimmune and other cell-mediated inflammatory diseases and conditions. It offers a dietary supplement under Colloral, The Collagen Solution, and Vital 3 brand names for treating the signs and symptoms of rheumatoid arthritis. The companyÂ’s products under development include MBP8298, which is in Phase III clinical trials for the treatment of secondary progressive multiple sclerosis, as well as in Phase II clinical trials for relapsing-remitting multiple sclerosis; Oral Copaxone that is in preclinical stage for the treatment of multiple sclerosis; and AI 401, which is in Phase III clinical trails for the treatment of Type I diabetes. AutoImmune has a joint venture with Deseret Laboratories, Inc. to manufacture, market, and sell Colloral as a dietary supplement. It also has collaboration agreements with The Brigham and WomenÂ’s Hospital and Eli Lilly and Company. The company was formerly AutoImmune Technologies, Inc. and changed its name to AutoImmune Inc. in July 1991. AutoImmune was founded in 1988 and is based in Pasadena, California.AutoImmune Inc. (AIMM:OTC Bulletin Board Market)
Snapshot of AutoImmune Inc. (AIMM)
|
OPEN
$0.42
|
PREVIOUS CLOSE
$0.38
|
|
|
DAY HIGH
$0.45
|
DAY LOW
$0.42
|
|
|
52 WEEK HIGH
07/22/09 - $1.50
|
52 WEEK LOW
10/28/09 - $0.32
|
|
|
MARKET CAP
7.7M
|
AVERAGE VOLUME 3 mo
22.9K
|
|
|
DILUTED EPS TTM
$-0.02
|
SHARES OUTSTANDING
17.0M
|
|
|
AIMM Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
AIMM Top Compensated Officers
Executives, Board Directors
Key developments for AutoImmune Inc. (AIMM)
AutoImmune Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. The company reported net income attributable to shareholders of $2,000, or $0.00 per share basic and diluted, for the three months ended September 30, 2009, compared with a net loss attributable to shareholders of $23,000, or $0.00 per share basic and diluted, for the three months ended September 30, 2008. Revenue was $237,000 against $57,000 reported a year ago. For the nine months ended September 30, 2009, the net loss attributable to shareholders was $254,000, or $0.01 per share basic and diluted, compared with net loss attributable to shareholders of $216,000, or $0.01 per share basic and diluted for the same period in 2008. Revenue was $525,000 against $225,000 reported a year ago.
AutoImmune Inc. announced on October 21, 2009 that its Board of Directors has authorized the exploration of a full range of strategic alternatives available to the Company in order to enhance shareholder value. AutoImmune has retained Junewicz & Co. Inc. as its financial advisor for this evaluation process. Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. said, “AutoImmune's Board of Directors believes that given the recently announced Phase III trial failure of dirucotide, the lead drug covered by AutoImmune's license agreement with BioMS Medical Corporation, it is appropriate and in the best interest of shareholders to retain Junewicz & Co. to explore and evaluate our strategic options. We have asked Junewicz & Co. to pursue all strategic options available to the Company, including, but not limited to, a sale or merger of the Company.”
AutoImmune Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2009. For the quarter, the company reported a net loss attributable to the company of $86,000, or $0.01 per diluted share, compared with a net loss of $86,000, or $0.01 per diluted share, for the three months ended June 30, 2008. The company's revenue was $184,000 compared with revenue of $101,000 for the same period a year ago. For the six months, the company's net loss attributable to the company was $256,000, or $0.02 per share basic and diluted, compared with net loss of $193,000, or $0.01 per share basic and diluted for the same period in 2008. The company's revenue was $288,000 compared with revenue of $168,000 for the same period a year ago.
AIMM Competitors
| Company | Last | Change | |
| No competitor information is available for AIMM. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | AIMM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 12.4x |
|
| Price/Book | 0.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.3x |
|
|
AIMM |
||